José Antonio Caminero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
José Antonio Caminero has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Battista Migliori
Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy
5 shared publications - José-María García-García
Programa Integrado de Investigación en Tuberculosis (PII TB) de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Barcelona, España; Unidad de Gestión Clínica de Neumología, Hospital Universitario San Agustín, Avilés, Asturias, España
4 shared publications - Adrian Rendon
Universidad Autonoma de Nuevo León, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Centro de Investigación, Prevención y Tratamiento de Infecciones Respiratorias (CIPTIR), Monterrey, Mexico
3 shared publications - Alberto Piubello
Damien Foundation, Brussels, Belgium
3 shared publications Anna Scardigli
The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland
3 shared publications- Joan Artur Caylà
Tuberculosis Research Unit Foundation of Barcelona, 08008 Barcelona, Spain
3 shared publications
Latest Publications
- 10 October 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (4) , 1901272
The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines
New shorter MDR-TB regimens based on drugs administered orallyhttp://bit.ly/2Nwg6lv
- 10 October 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (4) , 1901272
The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines
New shorter MDR-TB regimens based on drugs administered orallyhttp://bit.ly/2Nwg6lv
- Open Access
- 1 July 2019
- Published by Elsevier in The Lancet
- Vol. 394 (10195) , 298
Multidrug-resistant tuberculosis
- 1 July 2019
- Published by Elsevier in The Lancet
- Vol. 394 (10195) , 298
Open AccessMultidrug-resistant tuberculosis
- Open Access
- 1 June 2019
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 83, 72-76
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
- 1 June 2019
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 83, 72-76
Open AccessSurveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
- 1 August 2018
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 22 (8) , 831-832
The economic burden of multidrug-resistant tuberculosis
- 1 August 2018
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 22 (8) , 831-832
The economic burden of multidrug-resistant tuberculosis
- 1 May 2018
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 54 (5) , 298
Comments on the SEPAR Guidelines for the Diagnosis and Treatment of Drug-Resistant Tuberculosis
- 1 May 2018
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 54 (5) , 298
Comments on the SEPAR Guidelines for the Diagnosis and Treatment of Drug-Resistant Tuberculosis
- Open Access
- 10 March 2018
- Published by Taylor & Francis in Pulmonology
- Vol. 24 (2) , 132-141
Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond
As recommended by the World Health Organization (WHO), optimal management of MDR-TB cases can be ensured by a multi-speciality consultation body known as 'TB Consilium'. This body usually includes different medical specialities, competences and perspectives (e.g., clinical expertise both for adults and children; surgical, radiological and public health expertise; psychological background and nursing experience, among others), thus lowering the risk of making mistakes - or managing the patients inappropriately, in order to improve their clinical outcomes. At present, several high MDR-TB burden countries in the different WHO regions (and beyond) have introduced TB Consilium-like bodies at the national or subnational level to reach consensus on the best treatment approach for their patients affected by TB. In addition, in countries/settings where a formal system of consultation does not exist, specialized staff from MDR-TB reference centres or international organizations usually spend a considerable amount of their working time responding to phone or e-mail clinical queries on how to manage M/XDR-TB cases. The aim of this manuscript is to describe the different experiences with the TB Consilia both at the international level (European Respiratory Society - ERS/WHO TB Consilium) and in some of the countries where this experience operates successfully in Europe and beyond. The Consilium experiences are described around the following topics: (1) history, aims and focus; (2) management and funding; (3) technical functioning and structure; (4) results achieved. In addition a comparative analysis of the TB Consilia in the different countries has been performed.
- 10 March 2018
- Published by Taylor & Francis in Pulmonology
- Vol. 24 (2) , 132-141
Open AccessTeam approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond
As recommended by the World Health Organization (WHO), optimal management of MDR-TB cases can be ensured by a multi-speciality consultation body known as 'TB Consilium'. This body usually includes different medical specialities, competences and perspectives (e.g., clinical expertise both for adults and children; surgical, radiological and public health expertise; psychological background and nursing experience, among others), thus lowering the risk of making mistakes - or managing the patients inappropriately, in order to improve their clinical outcomes. At present, several high MDR-TB burden countries in the different WHO regions (and beyond) have introduced TB Consilium-like bodies at the national or subnational level to reach consensus on the best treatment approach for their patients affected by TB. In addition, in countries/settings where a formal system of consultation does not exist, specialized staff from MDR-TB reference centres or international organizations usually spend a considerable amount of their working time responding to phone or e-mail clinical queries on how to manage M/XDR-TB cases. The aim of this manuscript is to describe the different experiences with the TB Consilia both at the international level (European Respiratory Society - ERS/WHO TB Consilium) and in some of the countries where this experience operates successfully in Europe and beyond. The Consilium experiences are described around the following topics: (1) history, aims and focus; (2) management and funding; (3) technical functioning and structure; (4) results achieved. In addition a comparative analysis of the TB Consilia in the different countries has been performed.
- 1 September 2017
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 53 (9) , 501-509
Diagnóstico y tratamiento de la tuberculosis con resistencia a fármacos
- 1 September 2017
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 53 (9) , 501-509
Diagnóstico y tratamiento de la tuberculosis con resistencia a fármacos
- Open Access
- 5 July 2017
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 50 (1) , 1700648
Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases
A potential standardised regimen to manage extensively drug-resistant tuberculosis (XDR-TB) and pre-XDR caseshttp://ow.ly/LucH30bUjjH
- 5 July 2017
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 50 (1) , 1700648
Open AccessProposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases
A potential standardised regimen to manage extensively drug-resistant tuberculosis (XDR-TB) and pre-XDR caseshttp://ow.ly/LucH30bUjjH
- 1 August 2016
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 22 (8) , 526-531
Nontuberculous mycobacteria in cystic fibrosis patients on the Island of Gran Canaria. A population study
- 1 August 2016
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 22 (8) , 526-531
Nontuberculous mycobacteria in cystic fibrosis patients on the Island of Gran Canaria. A population study
- Open Access
- 30 September 2015
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 46 (4) , 887-893
Classification of antituberculosis drugs: a new proposal based on the most recent evidence
The classification of the anti-TB drugs should probably be modified to optimise the use old and new compounds http://ow.ly/QbDSP
- 30 September 2015
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 46 (4) , 887-893
Open AccessClassification of antituberculosis drugs: a new proposal based on the most recent evidence
The classification of the anti-TB drugs should probably be modified to optimise the use old and new compounds http://ow.ly/QbDSP